Home health remedies Ferrer unloads another business to focus on branded drugs

Ferrer unloads another business to focus on branded drugs


European pharma firm Grupo Ferrer is parting with three plants, 140 employees and an ingredients business as it narrows its focus on its branded pharmaceutical business. 

Ferrer has sold HealthTech BioActives (HTBA), a business centered on nutraceuticals, to U.S. private investment group The Riverside Company. Terms of the deal were not disclosed, but HTBA, which makes APIs, excipients, flavorings and sweeteners for the pharmaceutical, nutraceutical and cosmetic industries, had sales of €51 million in 2018, Riverside said.  

RELATED: Spanish API maker Interquim hit with FDA warning letter


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The deal includes two Spanish manufacturing plants—one in Barcelona and one in Beniel, Murcia—as well as the 140 employees working for the business, Riverside said. 

“We are very pleased to have reached this deal with Riverside,” Mario Rovirosa, CEO of Ferrer Pharmaceutical, said in a statement. “Not only does it reinforce our corporate strategy to focus on the branded pharma market, but it also offers a future of growth for HealthTech BioActives.”

The sale follows Ferrer’s deal earlier this year to unload its generics business, Tarbis Farma, to India’s Hetero for an undisclosed sum. Rovirosa began slimming Ferrer down after being named CEO in 2018.

Source link


Please enter your comment!
Please enter your name here

4 × 4 =